February 27, 2018 / 8:01 AM / in 6 months

BRIEF-Poxel Presents Preclinical Proof-Of-Concept Data For Pxl770

Feb 27 (Reuters) - POXEL SA:

* POXEL PRESENTS PRECLINICAL PROOF-OF-CONCEPT DATA FOR PXL770 IN NON-ALCOHOLIC STEATOHEPATITIS (NASH) AT GLOBAL NASH CONGRESS 2018

* PXL770 IS OBSERVED TO SIGNIFICANTLY REDUCE LIVER STEATOSIS AND NAS SCORE FOLLOWING 8 WEEKS OF TREATMENT VERSUS CONTROL

* PXL770 IS OBSERVED TO SIGNIFICANTLY REDUCE EXPRESSION OF A PANEL OF KEY GENES ASSOCIATED WITH FIBROSIS

* WE ARE PLANNING TO INITIATE A PHASE 2A PROOF-OF-CONCEPT STUDY IN PATIENTS WITH NAFLD -CEO

* STUDY IS EXPECTED TO BEGIN DURING SECOND HALF OF 2018

* WE ARE ALSO EXPLORING OTHER METABOLIC DISEASES FOR PROOF-OF-CONCEPT STUDIES FOR PXL770 -CEO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below